Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 29, 2009
JNCI Journal of the National Cancer Institute 2009 101(15):1033; doi:10.1093/jnci/djp234
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
101/15/1033    most recent
djp234v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

MEMO TO THE MEDIA

How much is life worth? The $440 Billion Question

The first 10% of the full text of this article appears below.

The decision to use expensive cancer therapies that typically produce only a relatively short extension of survival is a serious ethical dilemma in the U.S. that needs to be addressed by the oncology community, according to a commentary published online . . . [Full Text of this Article]

Citation:

Contact:

PDF:


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

How Much Is Life Worth: Cetuximab, Non–Small Cell Lung Cancer, and the $440 Billion Question
Tito Fojo and Christine Grady
J Natl Cancer Inst 2009 101: 1044-1048. [Abstract] [Full Text] [PDF]